-
Je něco špatně v tomto záznamu ?
Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy
A. Di Martino, V. Sedlarik,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- chitosan aplikace a dávkování chemie MeSH
- dakarbazin aplikace a dávkování analogy a deriváty chemie terapeutické užití MeSH
- doxorubicin aplikace a dávkování chemie terapeutické užití MeSH
- kyselina mléčná aplikace a dávkování chemická syntéza chemie MeSH
- lékové transportní systémy * MeSH
- lidé MeSH
- molekulární struktura MeSH
- nanočástice aplikace a dávkování chemie MeSH
- polymery aplikace a dávkování chemická syntéza chemie MeSH
- povrchově aktivní látky aplikace a dávkování chemie MeSH
- povrchové vlastnosti MeSH
- teplota MeSH
- velikost částic MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The aim of this work was to investigate the potential of an amphiphilic system comprising chitosan-grafted polylactide and carboxyl-functionalized polylactide acid as a carrier for the controlled release and co-release of two DNA alkylating drugs: doxorubicin and temozolomide. Polylactide and carboxyl-functionalized polylactide acid were obtained through direct melt polycondensation reaction, using methanesulfonic acid as a non-toxic initiator, and subsequently these were grafted to the chitosan backbone through a coupling reaction, utilizing 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide as a condensing agent. ATR-FTIR analysis and conductometric titration confirmed that a reaction between CS and PLA, PLACA2% and PLACA5% occurred. Chitosan-grafted-polylactide and polylactide-citric acid nanoparticles were prepared via the polyelectrolyte complex technique, applying dextran sulphate as a polyanion, and loaded with doxorubicin and temozolomide. The diameter of particles, ζ-potential and their relationship to temperature and pH were analysed in all formulations. Encapsulation, co-encapsulation efficiency and release studies were conducted in different physiological simulated environments and human serum. Results showed the continuous release of drugs without an initial burst in different physiological media.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031908
- 003
- CZ-PrNML
- 005
- 20151013104549.0
- 007
- ta
- 008
- 151005s2014 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2014.08.014 $2 doi
- 035 __
- $a (PubMed)25124059
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Di Martino, Antonio $u Polymer Centre, Faculty of Technology, Tomas Bata University in Zlin, nam. T.G. Masaryka 275, 76272 Zlin, Czech Republic; Centre of polymer systems, University Institute, Nad Ovčírnou 3685, 76001 Zlin, Czech Republic.
- 245 10
- $a Amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy / $c A. Di Martino, V. Sedlarik,
- 520 9_
- $a The aim of this work was to investigate the potential of an amphiphilic system comprising chitosan-grafted polylactide and carboxyl-functionalized polylactide acid as a carrier for the controlled release and co-release of two DNA alkylating drugs: doxorubicin and temozolomide. Polylactide and carboxyl-functionalized polylactide acid were obtained through direct melt polycondensation reaction, using methanesulfonic acid as a non-toxic initiator, and subsequently these were grafted to the chitosan backbone through a coupling reaction, utilizing 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide as a condensing agent. ATR-FTIR analysis and conductometric titration confirmed that a reaction between CS and PLA, PLACA2% and PLACA5% occurred. Chitosan-grafted-polylactide and polylactide-citric acid nanoparticles were prepared via the polyelectrolyte complex technique, applying dextran sulphate as a polyanion, and loaded with doxorubicin and temozolomide. The diameter of particles, ζ-potential and their relationship to temperature and pH were analysed in all formulations. Encapsulation, co-encapsulation efficiency and release studies were conducted in different physiological simulated environments and human serum. Results showed the continuous release of drugs without an initial burst in different physiological media.
- 650 _2
- $a chitosan $x aplikace a dávkování $x chemie $7 D048271
- 650 _2
- $a dakarbazin $x aplikace a dávkování $x analogy a deriváty $x chemie $x terapeutické užití $7 D003606
- 650 _2
- $a doxorubicin $x aplikace a dávkování $x chemie $x terapeutické užití $7 D004317
- 650 12
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyselina mléčná $x aplikace a dávkování $x chemická syntéza $x chemie $7 D019344
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a nanočástice $x aplikace a dávkování $x chemie $7 D053758
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a polymery $x aplikace a dávkování $x chemická syntéza $x chemie $7 D011108
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 650 _2
- $a povrchově aktivní látky $x aplikace a dávkování $x chemie $7 D013501
- 650 _2
- $a teplota $7 D013696
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sedlarik, Vladimir $u Centre of polymer systems, University Institute, Nad Ovčírnou 3685, 76001 Zlin, Czech Republic. Electronic address: sedlarik@ft.utb.cz.
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 474, č. 1-2 (2014), s. 134-45
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25124059 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151013104738 $b ABA008
- 999 __
- $a ok $b bmc $g 1092784 $s 915034
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 474 $c 1-2 $d 134-45 $e 20140812 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20151005